Back to Trial

Oracle Runs

Oracle findings and outcome history for Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects (NCT06688123).

Runs
5
Findings
5
Latest Run
Apr 6, 2026, 2:57 PM
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial NCT06688123 is active not recruiting per multiple sources, with estimated primary completion Mar 2026. No public results, topline readout, or efficacy data found in searches as of Apr 2026. Other SHR-3167 Ph1/2 trials show positive glucose lowering but not this exact trial.

Found Apr 6, 2026, 2:59 PMReviewed Apr 6, 2026, 3:00 PM
ClinicalTrialsclinicaltrials.gov
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
Status: Active, not recruiting. Estimated Primary Completion Date: March 30, 2026. No results posted.
Web Searchcdek.pharmacy.purdue.edu
Trial NCT06688123
Phase 2, Status: ACTIVE_NOT_RECRUITING. No results or readout mentioned.
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)

Will the results be positive?

NCT06688123 (SHR-3167-201, Phase 2 vs insulin glargine) is Active Not Recruiting with estimated primary completion 2026-03-30. No results, top-line, or public readout found. Related Phase 1 data (positive glucose-lowering) is not trial-specific.

Found Apr 6, 2026, 2:10 PMReviewed Apr 6, 2026, 2:25 PM
Web Searchclinicaltrials.gov
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
Phase 2 trial vs insulin glargine in insulin-naive T2D patients on metformin ± SGLT2i. Primary endpoint: HbA1c change to week 20. Status: Active, not recruiting. Est. primary completion: 2026-03-30. No results posted.
Web Searchdiabetesjournals.orgJun 20, 2025, 12:00 AM
829-P: Once-Weekly Insulin SHR-3167 in Healthy Subjects and Type 2 Diabetes Mellitus Participants
Phase 1 data: SHR-3167 showed dose-dependent HbA1c reduction (0.60% at 20 mg vs 0.37% IGlar) and good tolerability. Not this Phase 2 trial.
NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:33 PM
ClinicalTrialsclinicaltrials.govNov 24, 2025, 12:00 AM
Study Details | NCT06688123 | ClinicalTrials.gov
ClinicalTrials.gov lists active not recruiting; primary completion 2026-03-30; hasResults=false on the latest posted update.
NO_DECISIONDismissed91% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No Phase 2 public readout was found for NCT06688123. ClinicalTrials.gov still lists the study as active, not recruiting, with estimated primary completion on 2026-03-30. Hengrui’s public SHR-3167 disclosure located was Phase 1 ADA 2025 data, and a catalyst tracker still labels Phase 2 results as expected/pending.

Found Apr 3, 2026, 4:31 PMReviewed Apr 3, 2026, 4:46 PM
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06688123 | Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
ClinicalTrials.gov lists NCT06688123 as an active, not recruiting Phase 2 study of SHR-3167 vs insulin glargine, with estimated primary completion date 2026-03-30.
Sponsorhengrui.com
2025 ADA | Hengrui disclosed 9 diabetes studies including SHR-3167
Hengrui’s identified SHR-3167 public data were ADA 2025 Phase 1 posters in healthy subjects/T2DM and a healthy-subject comparison vs insulin glargine, not this Phase 2 trial readout.
Web Searchcatalystalert.io
JNGHF Drug Pipeline & Catalysts | Jiangsu Hengrui Pharmaceuticals
Catalyst tracker still shows SHR-3167 Phase 2 results as expected/pending rather than reported, supporting that no clear public outcome is available yet for this program.
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No public Phase 2 readout was found for NCT06688123. The live trial record still shows active, not recruiting with estimated primary completion on 2026-03-30, and sponsor materials list SHR-3167 only as a Phase II pipeline asset without trial-specific efficacy interpretation. That is insufficient for a positive/negative call.

Found Apr 1, 2026, 7:55 PMReviewed Apr 1, 2026, 7:55 PM
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06688123 | Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
ClinicalTrials.gov lists NCT06688123 as Phase 2, active not recruiting, with estimated primary completion 2026-03-30 and no public results/readout shown in the study snippet.
Sponsorhkexnews.hkSep 26, 2025, 12:00 AM
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Interim Report 2025
Hengrui's 2025 interim report pipeline places SHR-3167 under Diabetes in Phase II, but does not provide trial-specific topline efficacy or frame NCT06688123 as positive or negative.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.